Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. AIDS in the US: 1985-2004
3. Approval of antiretrovirals: 1987-2007
4. Survival of HIV infected individuals in Denmark
5. Outline of talk
6. HIV-1 lifecycle
7. US FDA approved antiretroviral drugs
8. Mechanisms of action of antiretroviral agents
9. US approved nucleoside/tide RT inhibitors
10. Nucleoside/nucleotide RT inhibitors
11. How do you choose which NRTI/NtRTI to use?
12. Potency of NRTI/NtRTIs in monotherapy studies
13. Pharmacokinetics of NRTIs/NtRTIs
14. Adverse effects of NRTIs
15. Antiretroviral agents: RT inhibition by NNRTI
16. US approved non-nucleoside RT inhibitors
17. Crystal structure of HIV reverse transcriptase
18. Non-nucleoside reverse transcriptase inhibitors
19. Adverse effects of NNRTIs
20. Study 903E: viral suppression results
21. Study 903E: mean change in CD4 cell count
22. Antiretroviral agents: inhibition of viral protease
23. PIs - competitive inhibitors of the protease
24. Currently approved protease inhibitors in the US
25. Protease inhibitors (PIs)
26. Pharmacokinetics of protease inhibitors
27. Reasons to use a boosted PI
28. Study M98-863: time to virologic response loss
29. Medications that interact with protease inhibitors
30. Likelihood of significant drug interactions
31. Complications of HIV and HAART
32. Physical manifestations of lipodystrophy
33. Other adverse effects of protease inhibitors
34. Study 720: virologic response results
35. Study 720: mean change in CD4 cell count
36. Study 720: mean values of CD4 cell count
37. Antiretroviral agents: inhibition of cell entry
38. HIV entry involves three distinct mechanisms
39. Maraviroc (Selzentry) safety and efficacy
40. The goal: sustained viral suppression
41. Collated results of HAART studies
42. Lack of durability in clinical cohort studies
43. Challenges to successful ART
44. Initial therapy choice for treatment-naive patient
45. The need to individualize therapy
46. IAS-USA guidelines for initial therapy, 2006
47. DHHS guidelines for initial therapy
48. EACS guidelines for initial therapy, 2005
49. Key factors for improved durability
50. Regimen choice and durability
51. Cell cycle state and antiretroviral drugs potency
52. Potency of AZT in activated HIV-infected cells
53. Potency of AZT in resting HIV-infected cells
54. Cell cycle impact on antiretroviral drugs
55. Mutation threshold of the regimen
56. Risk of resistance: LPV/RTV vs. NFV
57. Study 934: 96-week resistance results
58. When to start antiretroviral therapy?
59. Strat of antiretroviral therapy: global data
60. EACS ART initiation guidelines, 2005
61. DHHS initiation guidelines, 2006
62. IAS-USA initiation guidelines
63. Therapeutic crossroads
64. Therapeutic paradigm shift
65. Overcoming the risks of early treatment
66. Outcomes by timing of therapy
67. CD4 cell count and progression to AIDS
68. LPV/r-based regimen CD4 cell count model
69. Care delivery system and treatment strategy
70. Approaches to improve treatment durability
71. New directions in antiretroviral therapy

Topics Covered

• Data from recent past about AIDS
• HIV life cycle and mechanisms of action of antiretroviral agents
• Nucleoside-nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs): potency, pharmacokinetics and adverse effects
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
• Protease inhibitors (PIs)
• Cell entry inhibitors
• Initiation of antiretroviral therapy in the naive patient
• Health authorities' guidelines for initial therapy
• Key factors for improved durability
• Cell cycle and effect of antiviral agents
• Risks of early treatment
• New directions in antiretroviral therapy

Links

Series:

• Retroviruses

Categories:

• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Redfield, R. (2007, October 1). Antiretroviral therapy 2007, new concepts and lessons learned [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/POSM3351.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on October 28, 2018

Financial Disclosures

• Prof. Robert Redfield has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.